vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Claritev Corp (CTEV). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $246.6M, roughly 1.2× Claritev Corp). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs -32.7%, a 129.0% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs 6.2%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 2.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
ACAD vs CTEV — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $246.6M |
| Net Profit | $273.6M | $-80.6M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | -3.1% |
| Net Margin | 96.3% | -32.7% |
| Revenue YoY | 9.4% | 6.2% |
| Net Profit YoY | 90.3% | 41.6% |
| EPS (diluted) | $1.61 | $-4.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $246.6M | ||
| Q3 25 | $278.6M | $246.0M | ||
| Q2 25 | $264.6M | $241.6M | ||
| Q1 25 | $244.3M | $231.3M | ||
| Q4 24 | $259.6M | $232.1M | ||
| Q3 24 | $250.4M | $230.5M | ||
| Q2 24 | $242.0M | $233.5M | ||
| Q1 24 | $205.8M | $234.5M |
| Q4 25 | $273.6M | $-80.6M | ||
| Q3 25 | $71.8M | $-69.8M | ||
| Q2 25 | $26.7M | $-62.6M | ||
| Q1 25 | $19.0M | $-71.3M | ||
| Q4 24 | $143.7M | $-138.0M | ||
| Q3 24 | $32.8M | $-391.4M | ||
| Q2 24 | $33.4M | $-576.7M | ||
| Q1 24 | $16.6M | $-539.7M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | -3.1% | ||
| Q3 25 | 12.8% | 4.1% | ||
| Q2 25 | 12.2% | 6.9% | ||
| Q1 25 | 7.9% | 4.2% | ||
| Q4 24 | 59.1% | -17.8% | ||
| Q3 24 | 12.6% | -146.7% | ||
| Q2 24 | 12.6% | -224.4% | ||
| Q1 24 | 7.4% | -207.4% |
| Q4 25 | 96.3% | -32.7% | ||
| Q3 25 | 25.8% | -28.4% | ||
| Q2 25 | 10.1% | -25.9% | ||
| Q1 25 | 7.8% | -30.8% | ||
| Q4 24 | 55.4% | -59.4% | ||
| Q3 24 | 13.1% | -169.8% | ||
| Q2 24 | 13.8% | -247.0% | ||
| Q1 24 | 8.0% | -230.1% |
| Q4 25 | $1.61 | $-4.88 | ||
| Q3 25 | $0.42 | $-4.23 | ||
| Q2 25 | $0.16 | $-3.81 | ||
| Q1 25 | $0.11 | $-4.38 | ||
| Q4 24 | $0.86 | $-8.49 | ||
| Q3 24 | $0.20 | $-24.25 | ||
| Q2 24 | $0.20 | $-35.78 | ||
| Q1 24 | $0.10 | $-33.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $16.8M |
| Total DebtLower is stronger | — | $4.6B |
| Stockholders' EquityBook value | $1.2B | $-173.9M |
| Total Assets | $1.6B | $4.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $16.8M | ||
| Q3 25 | $258.0M | $39.2M | ||
| Q2 25 | $253.6M | $56.4M | ||
| Q1 25 | $217.7M | $23.1M | ||
| Q4 24 | $319.6M | $16.8M | ||
| Q3 24 | $155.1M | $86.6M | ||
| Q2 24 | $177.1M | $48.8M | ||
| Q1 24 | $204.7M | $58.7M |
| Q4 25 | — | $4.6B | ||
| Q3 25 | — | $4.5B | ||
| Q2 25 | — | $4.5B | ||
| Q1 25 | — | $4.5B | ||
| Q4 24 | — | $4.5B | ||
| Q3 24 | — | $4.5B | ||
| Q2 24 | — | $4.5B | ||
| Q1 24 | — | $4.5B |
| Q4 25 | $1.2B | $-173.9M | ||
| Q3 25 | $917.3M | $-101.8M | ||
| Q2 25 | $822.4M | $-39.9M | ||
| Q1 25 | $765.2M | $14.8M | ||
| Q4 24 | $732.8M | $84.0M | ||
| Q3 24 | $577.2M | $207.6M | ||
| Q2 24 | $516.7M | $603.4M | ||
| Q1 24 | $464.0M | $1.2B |
| Q4 25 | $1.6B | $4.9B | ||
| Q3 25 | $1.3B | $5.0B | ||
| Q2 25 | $1.2B | $5.1B | ||
| Q1 25 | $1.1B | $5.1B | ||
| Q4 24 | $1.2B | $5.2B | ||
| Q3 24 | $976.9M | $5.3B | ||
| Q2 24 | $914.1M | $5.7B | ||
| Q1 24 | $855.1M | $6.4B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 304.87× | ||
| Q4 24 | — | 53.67× | ||
| Q3 24 | — | 21.73× | ||
| Q2 24 | — | 7.48× | ||
| Q1 24 | — | 3.85× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $66.3M |
| Free Cash FlowOCF − Capex | — | $36.4M |
| FCF MarginFCF / Revenue | — | 14.8% |
| Capex IntensityCapex / Revenue | — | 12.1% |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-12.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $66.3M | ||
| Q3 25 | $74.3M | $19.9M | ||
| Q2 25 | $64.0M | $61.2M | ||
| Q1 25 | $20.3M | $-30.1M | ||
| Q4 24 | $40.4M | $-33.4M | ||
| Q3 24 | $63.2M | $72.8M | ||
| Q2 24 | $25.0M | $18.5M | ||
| Q1 24 | $29.1M | $49.7M |
| Q4 25 | — | $36.4M | ||
| Q3 25 | $73.9M | $-16.3M | ||
| Q2 25 | — | $36.6M | ||
| Q1 25 | — | $-68.9M | ||
| Q4 24 | — | $-63.8M | ||
| Q3 24 | $63.2M | $41.1M | ||
| Q2 24 | — | $-7.0M | ||
| Q1 24 | — | $19.2M |
| Q4 25 | — | 14.8% | ||
| Q3 25 | 26.5% | -6.6% | ||
| Q2 25 | — | 15.2% | ||
| Q1 25 | — | -29.8% | ||
| Q4 24 | — | -27.5% | ||
| Q3 24 | 25.2% | 17.8% | ||
| Q2 24 | — | -3.0% | ||
| Q1 24 | — | 8.2% |
| Q4 25 | — | 12.1% | ||
| Q3 25 | 0.1% | 14.7% | ||
| Q2 25 | — | 10.2% | ||
| Q1 25 | — | 16.8% | ||
| Q4 24 | — | 13.1% | ||
| Q3 24 | 0.0% | 13.8% | ||
| Q2 24 | — | 10.9% | ||
| Q1 24 | — | 13.0% |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 2.40× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
CTEV
Segment breakdown not available.
